OptiNose, Inc. (OPTN)
USD 9.4
(0.11%)
USD 9.4
(0.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -22.74 Million USD | 59.3% |
| 2022 | -55.89 Million USD | 15.88% |
| 2021 | -66.45 Million USD | 23.81% |
| 2020 | -87.21 Million USD | 8.77% |
| 2019 | -95.6 Million USD | 4.63% |
| 2018 | -100.24 Million USD | -106.55% |
| 2017 | -48.53 Million USD | -291.67% |
| 2016 | 25.32 Million USD | 190.18% |
| 2015 | -28.07 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -8.07 Million USD | -221.46% |
| 2024 Q2 | -6.54 Million USD | 18.91% |
| 2023 Q3 | -1.69 Million USD | 59.4% |
| 2023 Q4 | -2.51 Million USD | -48.29% |
| 2023 Q2 | -4.17 Million USD | 70.96% |
| 2023 FY | -22.74 Million USD | 59.3% |
| 2023 Q1 | -14.36 Million USD | -71.95% |
| 2022 Q4 | -8.35 Million USD | 22.63% |
| 2022 Q3 | -10.8 Million USD | 29.62% |
| 2022 Q2 | -15.34 Million USD | 28.28% |
| 2022 Q1 | -21.39 Million USD | -83.36% |
| 2022 FY | -55.89 Million USD | 15.88% |
| 2021 Q3 | -13.04 Million USD | 33.32% |
| 2021 Q2 | -19.55 Million USD | 11.87% |
| 2021 Q1 | -22.18 Million USD | -8.49% |
| 2021 FY | -66.45 Million USD | 23.81% |
| 2021 Q4 | -11.66 Million USD | 10.52% |
| 2020 Q4 | -20.45 Million USD | -14.36% |
| 2020 Q2 | -22.59 Million USD | 14.03% |
| 2020 Q3 | -17.88 Million USD | 20.86% |
| 2020 FY | -87.21 Million USD | 8.77% |
| 2020 Q1 | -26.28 Million USD | -14.68% |
| 2019 FY | -95.6 Million USD | 4.63% |
| 2019 Q2 | -25.7 Million USD | 5.36% |
| 2019 Q1 | -27.16 Million USD | -9.89% |
| 2019 Q4 | -22.92 Million USD | -15.71% |
| 2019 Q3 | -19.8 Million USD | 22.94% |
| 2018 Q1 | -29.04 Million USD | -47.48% |
| 2018 FY | -100.24 Million USD | -106.55% |
| 2018 Q4 | -24.71 Million USD | -5.22% |
| 2018 Q3 | -23.49 Million USD | -2.21% |
| 2018 Q2 | -22.98 Million USD | 20.88% |
| 2017 Q1 | -7.3 Million USD | -49.59% |
| 2017 Q2 | -8.33 Million USD | -14.16% |
| 2017 Q3 | -13.19 Million USD | -58.26% |
| 2017 Q4 | -19.69 Million USD | -49.28% |
| 2017 FY | -48.53 Million USD | -291.67% |
| 2016 FY | 25.32 Million USD | 190.18% |
| 2016 Q2 | -4.45 Million USD | -111.07% |
| 2016 Q3 | -5.62 Million USD | -26.27% |
| 2016 Q4 | -4.88 Million USD | 13.27% |
| 2016 Q1 | 40.28 Million USD | 0.0% |
| 2015 FY | -28.07 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 148.43% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -50.629% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 113.625% |
| Cosmos Health Inc. | -21.83 Million USD | -4.199% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -13.456% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 85.377% |
| Cronos Group Inc. | -81.37 Million USD | 72.046% |
| Incannex Healthcare Limited | -30.04 Million USD | 24.277% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 41.9% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 343.79% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -380.247% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -375.373% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -375.373% |
| SCYNEXIS, Inc. | 72.66 Million USD | 131.304% |
| Safety Shot Inc | -12.18 Million USD | -86.702% |
| Theratechnologies Inc. | -10.62 Million USD | -114.059% |
| Alpha Teknova, Inc. | -35.56 Million USD | 36.035% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -545.009% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 125.946% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -383.897% |
| Dynavax Technologies Corporation | -37.02 Million USD | 38.565% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 110.882% |
| Radius Health, Inc. | -3.92 Million USD | -479.567% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -804.415% |
| Alvotech | -354.86 Million USD | 93.59% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 85.727% |
| SIGA Technologies, Inc. | 83.62 Million USD | 127.204% |
| Shineco, Inc. | -17.06 Million USD | -33.295% |
| Silver Spike Investment Corp. | 7.34 Million USD | 409.914% |
| Journey Medical Corporation | -2.07 Million USD | -997.347% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -67.051% |
| Embecta Corp. | 221.5 Million USD | 110.27% |
| Harrow Health, Inc. | 580 Thousand USD | 4022.069% |
| Procaps Group, S.A. | 38.97 Million USD | 158.369% |
| Biofrontera Inc. | -22.67 Million USD | -0.313% |
| DURECT Corporation | -36.88 Million USD | 38.326% |
| PainReform Ltd. | -9.58 Million USD | -137.354% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -331.733% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 280.082% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 281.621% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -266.264% |
| ProPhase Labs, Inc. | -21.61 Million USD | -5.251% |
| Phibro Animal Health Corporation | 53.31 Million USD | 142.667% |
| Procaps Group S.A. | 52.32 Million USD | 143.475% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -166.901% |
| Viatris Inc. | 766.2 Million USD | 102.969% |
| Rockwell Medical, Inc. | -6.67 Million USD | -241.049% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -332.965% |
| Tilray Brands, Inc. | -174.74 Million USD | 86.982% |
| PetIQ, Inc. | 60.01 Million USD | 137.904% |
| Talphera, Inc. | -16.88 Million USD | -34.691% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 109.067% |
| Alimera Sciences, Inc. | -1.47 Million USD | -1446.431% |
| Assertio Holdings, Inc. | -243.53 Million USD | 90.659% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -286.058% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 83.498% |
| Hempacco Co., Inc. | -8.81 Million USD | -158.14% |
| Alvotech | -354.86 Million USD | 93.59% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 106.238% |
| Kamada Ltd. | 10.06 Million USD | 326.033% |
| Currenc Group, Inc. | -6.64 Million USD | -242.292% |
| Indivior PLC | -4 Million USD | -468.7% |
| Evoke Pharma, Inc. | -7.43 Million USD | -206.127% |
| Flora Growth Corp. | -50.35 Million USD | 54.824% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -13.456% |
| Evolus, Inc. | -49.23 Million USD | 53.795% |
| HUTCHMED (China) Limited | 18.37 Million USD | 223.799% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 111.548% |
| Akanda Corp. | -10.05 Million USD | -126.317% |